Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi reports positive trial data for Zaltrap

Sanofi reports positive trial data for Zaltrap

8th June 2011

Sanofi has reported a positive outcome from its latest clinical trial of Zaltrap, an oncology treatment developed in partnership with Regeneron Pharmaceuticals.

The company has conducted a phase III study called Velour, in which the drug – also known as VEGF Trap – was assessed among metastatic colorectal cancer patients previously treated with oxaliplatin.

When administered in combination with a Folfiri chemotherapy regimen, the drug was able to deliver improved rates of overall and progression-free survival compared to placebo.

Using this data, the company plans to submit marketing authorisation applications to both the European Medicines Agency and US Food and Drug Administration in the second half of 2011.

Dr Debasish Roychowdhury, senior vice-president and head of Sanofi Oncology, said: "We are excited by these results and are committed to bringing this novel therapy to patients as soon as possible."

Earlier this week, the company also reported data from a phase III trial of semuloparin, showing its efficacy in preventing venous thromboembolism among cancer patients.ADNFCR-8000103-ID-800571214-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.